Richmond Pharmacology presents further QT insulin data next month in San Diego!

Posted:
30
August 2012

30th August 2012

Richmond Pharmacology presents further QT insulin data next month in San Diego!

We welcome you to attend the 2012 Annual Meeting of the American College of Clinical Pharmacology (ACCP), taking place 23rd-25th September, at the Sheraton San Diego Hotel & Marina.This topic of this year's meeting is  Translating Clinical Pharmacology Research into Optimized Patient Care  and will encompass a series of Pre-meeting Workshops and Symposia on related content such as the role of clinical pharmacology in speeding the development of new anti-infective drugs to combat drug resistance, pharmacometrics in hospital-based pharmacotherapy, innovations in drug therapies, and much more.Join Richmond Pharmacology on Day 1, Sun 23rd Sep between 6 and 8pm, where we will present further data on studies using techniques such as the euglycaemic insulin clamp to probe the effect of insulin on the QT interval in healthy Caucasian and Japanese volunteers:

  • Late changes after a euglycaemic insulin clamp can lead to significant increases in QTcF in healthy subjects
  • The impact of insulin levels on QTc interval in Thorough QT studies conducted in healthy subjects

View full program

Latest news

Upcoming Event

ACCP 2020, Translating Clinical Pharmacology Research into Patient-centered Care

21 - 23 September 2020
Dr. Jorg Taubel will be presenting posters that explore the subjects of cardiac health and diabetes.
View event

Richmond Pharmacology is delighted to confirm partnership with Intellia Therapeutics

October 20, 2020
Phase I study of Intellia Therapeutic’s NTLA-2001 for the treatment of hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN)
Read more

Richmond Pharmacology supports ReViral with the development of Sisunatovir

September 9, 2020
ReViral has confirmed the FDA has granted Fast Track designation to Sisunatovir.
Read more

Richmond Pharmacology helps UK patients gain early access to ultra-rare disease drug Lumasiran

August 17, 2020
Richmond Pharmacology early phase drug development update.
Read more